(Associated Press) – New Jersey lawmakers advanced legislation Thursday that would permit doctors to authorize medical marijuana for any diagnosed condition.
Current law permits medical marijuana to be prescribed only for certain debilitating conditions.
The Assembly health committee approved the measure with Democrats supporting it and Republicans opposed. Three Democratic members didn’t vote and two Republicans abstained.
“There is no benefit in denying a patient relief,” Democratic Assemblyman Herb Conaway, who chairs the committee, said in a statement. “Medical marijuana has the potential to treat many medical conditions. If a doctor believes medical marijuana can be an effective treatment, then they should be able to prescribe it to their patients.”
Republican Assemblyman Brian Rumpf said before the vote that he had questions about whether such an expansion was supported by science. Rumpf voted against the measure.
The legislation increases the maximum amount of marijuana that can be dispensed in 30-day period from two ounces to four.
The measure also proposes a number of other changes to the state’s medical marijuana law, including authorizing a person to serve as a primary caregiver for up to two patients. That’s up from the current limitation of no more than one patient.
New Jersey Democratic Gov. Phil Murphy is pushing for legalizing recreational marijuana.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…